Keyword: Concerta

Janssen's workers at a plant in California will be let go over the next three years, staring with nearly 50 being whacked next week.

Johnson & Johnson says its new offerings and label expansions will help deliver "above-market" growth through 2021, despite pricing and biosim challenges.

J&J missed analyst expectations on pharma and consumer health sales in the first quarter as some of its stalwart performers shrank instead of grew.

Last week, Johnson & Johnson caught a break when the FDA kicked a pair of controversial copies of its ADHD med Concerta off the market. Now, there’s a new challenger stepping up to the plate, though--and that’s Mylan.

Generics of Johnson & Johnson’s ADHD pill Concerta are hitting hard times due to an FDA crackdown on their bioequivalence. The agency said six months ago that generics makers Lannett and Mallinckrodt had that much time to confirm their extended-release technology matched that of J&J’s.